Discontinuation report TEVA-DEFERASIROX
| Report ID | 97589 |
| Drug Identification Number | 02407973 |
| Brand name | TEVA-DEFERASIROX |
| Common or Proper name | DEFERASIROX |
| Company Name | TEVA CANADA LIMITED |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | DEFERASIROX |
| Strength(s) | 500MG |
| Dosage form(s) | TABLET FOR SUSPENSION |
| Route of administration | ORAL |
| Packaging size | 30 |
| ATC code | V03AC |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2019-10-31 |
| Actual discontinuation date | 2019-10-31 |
| Remaining supply date | 2019-10-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2019-10-31 | English | Compare |
| v2 | 2019-10-31 | French | Compare |
| v3 | 2019-11-01 | English | Compare |
Showing 1 to 3 of 3